Orakl Oncology raises €30M Series A to predict cancer drug trial outcomes with AI
EU-Startups Funding· David Cendon Garcia·· 5 days agoTop DealsAI Score65
Orakl Oncology raises €30M Series A to predict cancer drug trial outcomes with AI
Can AI predict which cancer drugs will actually work? Orakl Oncology raises €30 million to find out
AI Overview
Orakl Oncology, a French TechBio spun out of the Gustave Roussy Institute, raised a €30M ($34M) Series A co-led by Norrsken VC and Singular.
Why it matters
The round shows investors backing a platform that pairs patient-derived tumor organoids with AI to forecast trial outcomes, a concrete bet on cutting late-stage oncology failure.